These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 11875307)

  • 1. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study.
    Wachtell K; Olsen MH; Dahlöf B; Devereux RB; Kjeldsen SE; Nieminen MS; Okin PM; Papademetriou V; Mogensen CE; Borch-Johnsen K; Ibsen H
    J Hypertens; 2002 Mar; 20(3):405-12. PubMed ID: 11875307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction.
    Wachtell K; Palmieri V; Olsen MH; Bella JN; Aalto T; Dahlöf B; Gerdts E; Wright JT; Papademetriou V; Mogensen CE; Borch-Johnsen K; Ibsen H; Devereux RB
    Am Heart J; 2002 Feb; 143(2):319-26. PubMed ID: 11835038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of microalbuminuria and ECG left ventricular hypertrophy in hypertensive patients in private practices in South Africa.
    Rayner B; Becker P
    Cardiovasc J S Afr; 2006; 17(5):245-9. PubMed ID: 17117229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
    J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Dahlöf B
    Hypertension; 2000 Nov; 36(5):766-73. PubMed ID: 11082141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
    Bang CN; Devereux RB; Okin PM
    J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
    Okin PM; Jern S; Devereux RB; Kjeldsen SE; Dahlöf B;
    Hypertension; 2000 Jan; 35(1 Pt 1):13-8. PubMed ID: 10642268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM
    J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
    Palmieri V; Okin PM; de Simone G; Bella JN; Wachtell K; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
    J Hypertens; 2007 May; 25(5):1079-85. PubMed ID: 17414673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
    Okin PM; Devereux RB; Jern S; Julius S; Kjeldsen SE; Dahlöf B
    Am J Hypertens; 2001 Aug; 14(8 Pt 1):775-82. PubMed ID: 11497193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of left ventricular hypertrophy by different electrocardiographic criteria in clinical practice. Findings from the Sara study.
    Calderón A; Barrios V; Escobar C; Ferrer E; Barrios S; González-Pedel V; Montoro P; Navarro-Cid J
    Clin Exp Hypertens; 2010 May; 32(3):145-53. PubMed ID: 20504121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
    Palmieri V; Okin PM; Bella JN; Gerdts E; Wachtell K; Gardin J; Papademetriou V; Nieminen MS; Dahlöf B; Devereux RB;
    Hypertension; 2003 Jan; 41(1):75-82. PubMed ID: 12511533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
    Okin PM; Wright JT; Nieminen MS; Jern S; Taylor AL; Phillips R; Papademetriou V; Clark LT; Ofili EO; Randall OS; Oikarinen L; Viitasalo M; Toivonen L; Julius S; Dahlöf B; Devereux RB
    Am J Hypertens; 2002 Aug; 15(8):663-71. PubMed ID: 12160187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
    Søraas CL; Wachtell K; Okin PM; Dahlöf B; Devereux RB; Tønnessen T; Kjeldsen SE; Olsen MH
    Blood Press; 2010 Jun; 19(3):145-51. PubMed ID: 20429689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and covariates of electrocardiographic left ventricular hypertrophy in diabetic patients in Tanzania.
    Lutale JJ; Thordarson H; Gulam-Abbas Z; Vetvik K; Gerdts E
    Cardiovasc J Afr; 2008; 19(1):8-14. PubMed ID: 18320079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
    Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy.
    Okin PM; Gerdts E; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B; Devereux RB;
    Hypertension; 2008 Jul; 52(1):100-6. PubMed ID: 18504323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
    JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-Grade Albuminuria Is Associated with Left Ventricular Hypertrophy and Diastolic Dysfunction in Patients with Hypertension.
    Wang T; Zhong H; Lian G; Cai X; Gong J; Ye C; Xie L
    Kidney Blood Press Res; 2019; 44(4):590-603. PubMed ID: 31387099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The relationship between isolated nocturnal hypertension and left ventricular hypertrophy].
    Lu L; Li Y; Huang QF
    Zhonghua Nei Ke Za Zhi; 2008 Oct; 47(10):819-22. PubMed ID: 19080140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.